LANTUS SOLOSTAR
INSULIN GLARGINE RECOMBINANT
Approval overview LANTUS SOLOSTAR is listed in Drugs@FDA under application 021081 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient INSULIN GLARGINE RECOMBINANT Form and strength INJECTABLE;INJECTION - 300 UNITS/3ML (100 UNITS/ML) Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 2023-06-29 00:00:00.
Structured Monograph
Clinical summary
Approval overview LANTUS SOLOSTAR is listed in Drugs@FDA under application 021081 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient INSULIN GLARGINE RECOMBINANT Form and strength INJECTABLE;INJECTION - 300 UNITS/3ML (100 UNITS/ML) Sponsor SANOFI AVENTIS US Submission history Latest submission status date: 2023-06-29 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.